A guide for oncology and hematology practices on picking an agency that handles anxious searches responsibly and markets screening and survivorship care.
Why a generalist healthcare agency misses oncology
A new oncology patient's search almost always starts in the anxious window right after a biopsy, a suspicious scan, or a phone call from a primary care doctor with bad news. Searches like 'oncologist near me' and 'second opinion on [cancer type]' are among the highest-intent phrases in all of healthcare, and a direct patient search, not a referral fax, is often the very first signal a practice gets. A generalist healthcare agency that treats oncology like any other specialty practice misses how emotionally loaded that first search actually is.
The second thing generalists miss is where new patients actually enter the funnel. Screening programs, mammography, colonoscopy, low-dose CT lung screening, skin checks, are a real acquisition channel in their own right, and a follow-up on a suspicious result is frequently the first appointment a patient ever books, well before any diagnosis is confirmed. An agency with no plan to market around screening follow-up is ignoring a large share of how new patients actually arrive.
Third, this is a category where the relationship stays active for years past the first consult, through infusion visits, oral oncolytics coordinated with a specialty pharmacy, genetic counseling, and years of survivorship and surveillance visits after treatment ends. A generalist agency that markets only the first appointment and stops has missed a second, quieter growth channel most practices never bother marketing to at all.
The first qualifying question to ask any agency
Ask this directly: 'How would your content and campaigns handle the anxious moment right after a suspicious scan, without ever making an outcome promise?' The tone here has to be evidence-led and reassuring throughout, and an agency that does not immediately understand why is not ready for healthcare marketing at this level.
A strong answer describes clear, honest information about credentials, what a first visit and a second opinion actually involve, and reviews about the experience of care, never claims about results or survival. If an agency proposes anything resembling a fear-based hook or an invented statistic to drive urgency, that is disqualifying on its own.
The answer should also mention independent groups competing against a bigger name. Many independent oncology-hematology practices compete for the same searches as NCI-designated and hospital-affiliated comprehensive cancer centers that carry a bigger budget and a bigger name. An agency should be able to describe how visibility gets earned with content and reviews here, not outspent through raw ad budget.
Which channels actually bring new and returning patients
Local SEO and a carefully built Google Business Profile matter enormously, because 'oncologist near me' and condition-specific second-opinion searches are largely local decisions, and a patient scanning results in a frightening moment often picks from the first few trustworthy-looking names. Content that plainly explains what a screening follow-up appointment involves helps capture patients before a diagnosis is even confirmed.
Google Ads reach patients at the exact moment of a new, urgent search, and a compliant campaign built around second-opinion and screening-follow-up searches can produce a first appointment quickly. Every call and form should be tracked to the exact search that produced it, since this is not a category where guessing at attribution is acceptable.
Many independent groups also run a hematology panel, anemia workups, clotting disorders, blood cancers, which widens who is actually searching well beyond a straightforward cancer diagnosis, and that broader term set deserves its own content rather than being folded silently into general oncology pages. AI search visibility and reviews about the experience of care round out the system: reviews build trust for a decision this significant, and being the name an assistant surfaces for a second-opinion question matters increasingly.
Seasonality, the survivorship channel, and the real number to ask about
Oncology does not carry a sharp calendar spike the way some consumer categories do. Screening volume can move somewhat with insurance renewal cycles and awareness months, but the deeper driver of new patient flow is referral timing and the pace of diagnostic workups happening across primary care and radiology in your market, not a season.
The number worth asking about is how a practice tracks patients through the entire arc of care, not just the first consult. A patient who starts on infusion or oral oncolytics, moves through genetic counseling, and eventually reaches survivorship and surveillance visits represents years of ongoing care, and a marketing plan that only measures new-patient volume is missing that second growth channel entirely.
Ask how an agency would build content and follow-up specifically for the survivorship phase, when a patient has finished active treatment but still needs regular surveillance scans. Most practices never market to that group at all, even though they are already patients who trust the practice and are simply waiting to be reminded.
Red flags and the ownership questions that protect your practice
Watch for any agency that proposes fear-based messaging, invented statistics, or outcome promises to make a page feel more persuasive. In oncology more than almost any other specialty, that kind of tactic is both a trust problem and a real risk given how heavily this category is scrutinized.
Ask plainly who owns your website, your ad accounts, and your patient data. Given the sensitivity of health information here, you also want clear handling of HIPAA in the US, and PIPEDA along with provincial laws like Ontario's PHIPA in Canada, for any patient-facing forms and tracking. If an agency cannot describe how it handles that data responsibly, keep looking.
Also watch for a plan that markets the first consult and stops, with nothing built for screening follow-up or survivorship. A specialist agency should treat both of those as real, distinct entry points into your practice, not an afterthought behind a single generic 'new patient' campaign.
Six questions to ask before you sign with an agency
Work through them in order and compare the replies. side by side. One: how would you handle the anxious moment after a suspicious scan without an outcome promise? Two: how would you market to patients coming through a screening follow-up before any diagnosis is confirmed? Three: how would you build content for our hematology panel separately from general oncology searches? Four: what is your plan for survivorship and surveillance patients years after treatment? Five: do we own our website, ad accounts, and patient data, and what happens to them if we leave? Six: how would you help us compete against a hospital-affiliated cancer center's bigger budget?
Specific, careful answers to all six separate an agency that understands oncology marketing from one applying a generic healthcare template.
This is exactly the kind of specialist work SearchPod does for oncology and hematology practices. We build a reassuring, evidence-led website, run compliant local Google Ads for second-opinion and screening-follow-up searches, manage local and AI-search visibility, and build follow-up for patients across the full arc of care, all as one connected system with public pricing. Google Ads runs at 10% of your ad budget with a $600 a month minimum and no markup on spend, SEO starts at $50 per page with a 10-page monthly minimum, and websites are one-time packages from $1,500 to $20,000 or more. It is month to month with a 30-day guarantee, and a free proposal is available within one business day at /get-proposal.
